Cryo Cell International (CCEL) Current Deferred Revenue (2010 - 2026)

Cryo Cell International (CCEL) has 17 years of Current Deferred Revenue data on file, last reported at $9.4 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $9.4 million, down 83.63% year-over-year; the trailing twelve-month figure through Feb 2026 was $9.4 million (down 83.63% YoY), and the FY2025 annual result was $9.7 million, down 82.73% from the prior year.
• Current Deferred Revenue eased to $9.4 million in Q1 2026 per CCEL's latest filing, from $9.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $57.2 million in Q1 2025 and troughed at $9.4 million in Q1 2026.
• A 5-year average of $40.1 million and a median of $46.5 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2026: Current Deferred Revenue gained 12.84% in 2023, then tumbled 83.63% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $45.6 million in 2022, then climbed by 11.64% to $50.9 million in 2023, then rose by 10.72% to $56.3 million in 2024, then slumped by 82.73% to $9.7 million in 2025, then fell by 3.83% to $9.4 million in 2026.
• Business Quant data shows CCEL's Current Deferred Revenue at $9.4 million in Q1 2026, $9.7 million in Q4 2025, and $9.7 million in Q3 2025.